Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Not intended to diagnose, treat or cure disease
Site reactions independent of dose magnitude appears at low and high doses similarly
The move does not indicate any partnership between Vital Proteins and Supergut, nor does it mean Vital Proteins plans to enter the GLP-1 supplement space
Short-Acting vs Long-Acting Formulations Short-acting GLP-1 medications have shorter half-lives and more frequent dosing: Exenatide immediate-release (Byetta) Half-life of approximately 24 hours, administered twice daily Lixisenatide (Lyxumia) Half-life of approximately 3 hours, administered once daily [19] Long-acting formulations demonstrate markedly different pharmacokinetics: Semaglutide Half-life of approximately 7 days (168 hours), administered weekly Dulaglutide Half-life of approximately 5 days (120 hours), administered weekly Liraglutide Half-life of approximately 13 hours, administered daily Exenatide extended-release Half-life of approximately 2 weeks, administered weekly Clearance Pathways GLP-1 medications are eliminated from the body through different pathways depending on the specific agent: Exenatide and lixisenatide are primarily eliminated through the kidneys
